艾伯维宣布与Gilgamesh Pharmaceuticals公司宣布达成一项确定性协议,将收购其一款用于治疗中度至重度抑郁症(MDD)的在研候选药物5-HT2A受体激动剂兼5-HT释放剂bretisilocin。
艾伯维宣布与Gilgamesh Pharmaceuticals公司宣布达成一项确定性协议,将收购其一款用于治疗中度至重度抑郁症(MDD)的在研候选药物5-HT2A受体激动剂兼5-HT释放剂bretisilocin。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.